Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings; Rogier  Mous; Michael  Roost Clausen; Peter Johnson; Kim M. Linton; Martine E.D.  Chamuleau; David John Lewis; Anna Sureda Balari; David Cunningham; Roberto S. Oliveri; Dena DeMarco; Brian Elliott; Kuo-mei Chen; Pieternella J. Lugtenburg

doi:10.1182/blood-2020-133820

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings
, Rogier Mous
, Michael Roost Clausen
, Peter Johnson
, Kim M. Linton
, Martine E.D. Chamuleau
, David John Lewis
, Anna Sureda Balari
, David Cunningham
, Roberto S. Oliveri
, Dena DeMarco
, Brian Elliott
, Kuo-mei Chen
, Pieternella J. Lugtenburg

IRS - Sygehus Lillebælt, Forskningsenhed for Hæmatologi (Vejle)

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Dansk
Tidsskrift	Blood
Vol/bind	136
Udgave nummer	Suppl. 1
Sider (fra-til)	45-46
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2020-133820
Status	Udgivet - 5. nov. 2020

Dokumenter og links

10.1182/blood-2020-133820

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Hutchings, M., Mous, R., Roost Clausen, M., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Balari, A. S., Cunningham, D., Oliveri, R. S., DeMarco, D., Elliott, B., Chen, K., & J. Lugtenburg, P. (2020). Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. Blood, 136(Suppl. 1), 45-46. https://doi.org/10.1182/blood-2020-133820

@article{515334dc5ae94fa993f4c8bfe87ced74,

title = "Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data",

author = "Martin Hutchings and Rogier Mous and \{Roost Clausen\}, Michael and Peter Johnson and Linton, \{Kim M.\} and Chamuleau, \{Martine E.D.\} and Lewis, \{David John\} and Balari, \{Anna Sureda\} and David Cunningham and Oliveri, \{Roberto S.\} and Dena DeMarco and Brian Elliott and Kuo-mei Chen and \{J. Lugtenburg\}, Pieternella",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/blood-2020-133820",

language = "Dansk",

volume = "136",

pages = "45--46",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Suppl. 1",

}

Hutchings, M, Mous, R, Roost Clausen, M, Johnson, P, Linton, KM, Chamuleau, MED, Lewis, DJ, Balari, AS, Cunningham, D, Oliveri, RS, DeMarco, D, Elliott, B, Chen, K & J. Lugtenburg, P 2020, 'Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data', Blood, bind 136, nr. Suppl. 1, s. 45-46. https://doi.org/10.1182/blood-2020-133820

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. / Hutchings, Martin; Mous, Rogier ; Roost Clausen, Michael et al.
I: Blood, Bind 136, Nr. Suppl. 1, 05.11.2020, s. 45-46.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy

T2 - Updated Dose Escalation Data

AU - Hutchings, Martin

AU - Mous, Rogier

AU - Roost Clausen, Michael

AU - Johnson, Peter

AU - Linton, Kim M.

AU - Chamuleau, Martine E.D.

AU - Lewis, David John

AU - Balari, Anna Sureda

AU - Cunningham, David

AU - Oliveri, Roberto S.

AU - DeMarco, Dena

AU - Elliott, Brian

AU - Chen, Kuo-mei

AU - J. Lugtenburg, Pieternella

PY - 2020/11/5

Y1 - 2020/11/5

U2 - 10.1182/blood-2020-133820

DO - 10.1182/blood-2020-133820

M3 - Konferenceabstrakt i tidsskrift

SN - 0006-4971

VL - 136

SP - 45

EP - 46

JO - Blood

JF - Blood

IS - Suppl. 1

ER -

Hutchings M, Mous R, Roost Clausen M, Johnson P, Linton KM, Chamuleau MED et al. Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. Blood. 2020 nov. 5;136(Suppl. 1):45-46. doi: 10.1182/blood-2020-133820